{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T02:09:16Z","timestamp":1777860556749,"version":"3.51.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00296-021-05056-2","type":"journal-article","created":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T17:02:46Z","timestamp":1637859766000},"page":"101-113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The incidence, clinical characteristics, and outcome of COVID-19 in a prospectively followed cohort of patients with Beh\u00e7et\u2019s syndrome"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4774-9284","authenticated-orcid":false,"given":"Guzin","family":"Ozcifci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8125-4808","authenticated-orcid":false,"given":"Tahacan","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2959-0978","authenticated-orcid":false,"given":"Zeynep","family":"Atli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8977-5931","authenticated-orcid":false,"given":"Ilker Inanc","family":"Balkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8632-2825","authenticated-orcid":false,"given":"Fehmi","family":"Tabak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-1374","authenticated-orcid":false,"given":"Mert","family":"Oztas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2082-4715","authenticated-orcid":false,"given":"Yesim","family":"Ozguler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9561-2282","authenticated-orcid":false,"given":"Serdal","family":"Ugurlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1952-1135","authenticated-orcid":false,"given":"Gulen","family":"Hatemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-8368","authenticated-orcid":false,"given":"Melike","family":"Melikoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-9690","authenticated-orcid":false,"given":"Izzet","family":"Fresko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6625-1652","authenticated-orcid":false,"given":"Vedat","family":"Hamuryudan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4965-2918","authenticated-orcid":false,"given":"Emire","family":"Seyahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"5056_CR1","unstructured":"https:\/\/www.worldometers.info\/coronavirus\/#countries. Accessed 7 September 2021"},{"key":"5056_CR2","unstructured":"https:\/\/www.aa.com.tr\/en\/latest-on-coronavirus-outbreak\/turkey-confirms-first-case-of-coronavirus\/1761522. Accessed 11 March 2020"},{"issue":"11","key":"5056_CR3","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1007\/s10067-020-05334-7","volume":"39","author":"C Ferri","year":"2020","unstructured":"Ferri C, Giuggioli D, Raimondo V, L\u2019Andolina M, Tavoni A, Cecchetti R, Guiducci S, Ursini F, Caminiti M, Varcasia G, Gigliotti P, Pellegrini R, Olivo D, Colaci M, Murdaca G, Brittelli R, Mariano GP, Spinella A, Bellando-Randone S, Aiello V, Bilia S, Giannini D, Ferrari T, Caminiti R, Brusi V, Meliconi R, Fallahi P, Antonelli A, COVID-19 & ASD Italian Study Group (2020) COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series. Clin Rheumatol. 39(11):3195\u20133204. https:\/\/doi.org\/10.1007\/s10067-020-05334-7","journal-title":"Clin Rheumatol."},{"issue":"12","key":"5056_CR4","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1136\/annrheumdis-2020-218296","volume":"79","author":"JL Pablos","year":"2020","unstructured":"Pablos JL, Galindo M, Carmona L, Lled\u00f3 A, Retuerto M, Blanco R, Gonzalez-Gay MA, Martinez-Lopez D, Castrej\u00f3n I, Alvaro-Gracia JM, Fern\u00e1ndez Fern\u00e1ndez D, Mera-Varela A, Manrique-Arija S, Mena V\u00e1zquez N, Fernandez-Nebro A, RIER Investigators Group; RIER investigators group (2020) Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. 79(12):1544\u20131549. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218296","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"5056_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1046\/j.1365-4362.2003.01893.x","volume":"42","author":"G Azizlerli","year":"2003","unstructured":"Azizlerli G, K\u00f6se AA, Sarica R, G\u00fcl A, Tutkun IT, Kula\u00e7 M, Tun\u00e7 R, Urgancio\u011flu M, Di\u015f\u00e7i R (2003) Prevalence of Beh\u00e7et\u2019s disease in Istanbul. Turkey Int J Dermatol 42(10):803\u2013806. https:\/\/doi.org\/10.1046\/j.1365-4362.2003.01893.x","journal-title":"Turkey Int J Dermatol"},{"issue":"2","key":"5056_CR6","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","volume":"14","author":"H Yazici","year":"2018","unstructured":"Yazici H, Seyahi E, Hatemi G, Yazici Y (2018) Beh\u00e7et syndrome: a contemporary view. Nat Rev Rheumatol. 14(2):107\u2013119. https:\/\/doi.org\/10.1038\/nrrheum.2017.208 (Epub 2018 Jan 3. Erratum in: Nat Rev Rheumatol. 2018 Jan 24;14 (2):119)","journal-title":"Nat Rev Rheumatol."},{"issue":"5","key":"5056_CR7","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1056\/NEJM199002013220501","volume":"322","author":"H Yazici","year":"1990","unstructured":"Yazici H, Pazarli H, Barnes CG, T\u00fcz\u00fcn Y, Ozyazgan Y, Silman A, Serdaro\u011flu S, O\u011fuz V, Yurdakul S, Lovatt GE et al (1990) A controlled trial of azathioprine in Beh\u00e7et\u2019s syndrome. N Engl J Med 322(5):281\u2013285. https:\/\/doi.org\/10.1056\/NEJM199002013220501 (PMID: 2404204)","journal-title":"N Engl J Med"},{"issue":"3","key":"5056_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","volume":"45","author":"C Mat","year":"2006","unstructured":"Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, Fresko I, Yazici H (2006) A double-blind trial of depot corticosteroids in Beh\u00e7et\u2019s syndrome. Rheumatology (Oxford) 45(3):348\u2013352. https:\/\/doi.org\/10.1093\/rheumatology\/kei165 (Epub 2005 Nov 1 PMID: 16263779)","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"5056_CR9","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/art.21231","volume":"52","author":"I Tugal-Tutkun","year":"2005","unstructured":"Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, G\u00fcl A (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Beh\u00e7et\u2019s disease: an open-label trial. Arthritis Rheum 52(8):2478\u20132484. https:\/\/doi.org\/10.1002\/art.21231 (PMID: 16052571)","journal-title":"Arthritis Rheum"},{"issue":"9","key":"5056_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/art.40531","volume":"70","author":"G Emmi","year":"2018","unstructured":"Emmi G, Vitale A, Silvestri E, Boddi M, Becatti M, Fiorillo C, Fabiani C, Frediani B, Emmi L, Di Scala G, Goldoni M, Bettiol A, Vaglio A, Cantarini L, Prisco D (2018) Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Beh\u00e7et\u2019s Syndrome: a Retrospective Study of Seventy Patients With Vascular Involvement. Arthritis Rheumatol 70(9):1500\u20131507. https:\/\/doi.org\/10.1002\/art.40531 (Epub 2018 Jul 19 PMID: 29676522)","journal-title":"Arthritis Rheumatol"},{"key":"5056_CR11","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jaut.2015.06.005","volume":"62","author":"H Vallet","year":"2015","unstructured":"Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D, French Beh\u00e7et Network (2015) Efficacy of anti-TNF alpha in severe and\/or refractory Beh\u00e7et\u2019s disease: Multicenter study of 124 patients. J Autoimmun 62:67\u201374. https:\/\/doi.org\/10.1016\/j.jaut.2015.06.005","journal-title":"J Autoimmun"},{"issue":"11","key":"5056_CR12","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::aid-art448>3.0.co;2-h","volume":"44","author":"S Yurdakul","year":"2001","unstructured":"Yurdakul S, Mat C, T\u00fcz\u00fcn Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H (2001) A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome. Arthritis Rheum 44(11):2686\u20132692. https:\/\/doi.org\/10.1002\/1529-0131(200111)44:11%3c2686::aid-art448%3e3.0.co;2-h (PMID: 11710724)","journal-title":"Arthritis Rheum"},{"issue":"5","key":"5056_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s10165-009-0200-2","volume":"19","author":"F Davatchi","year":"2009","unstructured":"Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji A, Shams H, Chams-Davatchi C (2009) Colchicine versus placebo in Beh\u00e7et\u2019s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol 19(5):542\u2013549. https:\/\/doi.org\/10.1007\/s10165-009-0200-2 (Epub 2009 Jul 14 PMID: 19597921)","journal-title":"Mod Rheumatol"},{"issue":"8","key":"5056_CR14","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s11739-020-02427-8","volume":"15","author":"B Yurtta\u015f","year":"2020","unstructured":"Yurtta\u015f B, Oztas M, Tunc A, Balkan \u0130\u0130, Tabak OF, Hamuryudan V, Seyahi E (2020) Characteristics and outcomes of Beh\u00e7et\u2019s syndrome patients with Coronavirus Disease 2019: a case series of 10 patients. Intern Emerg Med 15(8):1567\u20131571. https:\/\/doi.org\/10.1007\/s11739-020-02427-8 (Epub 2020 Jul 9)","journal-title":"Intern Emerg Med"},{"key":"5056_CR15","doi-asserted-by":"publisher","first-page":"651715","DOI":"10.3389\/fimmu.2021.651715","volume":"12","author":"SN Esatoglu","year":"2021","unstructured":"Esatoglu SN, Tascilar K, Babao\u011flu H, Bes C, Yurttas B, Akar S, Pehlivan O, Akleylek C, Tecer D, Seyahi E, Yuce-Inel T, Alpay-Kanitez N, Bodakci E, Tekgoz E, Colak S, Bolek EC, Koca SS, Kalyoncu U, Icacan OC, Ugurlu S, Oz HE, Hamuryudan V, Hatemi G, Turkish Society for Rheumatology COVID-19 Registry Investigators (2021) COVID-19 among patients with inflammatory rheumatic diseases. Front Immunol. 12:651715. https:\/\/doi.org\/10.3389\/fimmu.2021.651715","journal-title":"Front Immunol."},{"issue":"5","key":"5056_CR16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.55563\/clinexprheumatol\/pmnqmf","volume":"132","author":"I Mattioli","year":"2021","unstructured":"Mattioli I, Bettiol A, Silvestri E, Urban ML, Palermo A, Fagni F, Malandrino D, Del Bianco A, Prisco D, Emmi G (2021) Prevalence and clinical course of SARS-CoV-2 infection in patients with Beh\u00e7et\u2019s syndrome. Clin Exp Rheumatol. 132(5):47\u201350 (Epub 2021 Jun 9. PMID: 34128795.)","journal-title":"Clin Exp Rheumatol."},{"key":"5056_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217778","author":"G Espinosa","year":"2020","unstructured":"Espinosa G, Araujo O, Amaro S, Bodro M, Moreno PJ, Moreno R, Ugarte A, Cervera R (2020) COVID-19 and Beh\u00e7et\u2019s disease: clinical case series. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217778","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"5056_CR18","doi-asserted-by":"publisher","first-page":"e541","DOI":"10.1111\/jdv.17325","volume":"35","author":"CC Zouboulis","year":"2021","unstructured":"Zouboulis CC, van Laar JAM, Schirmer M, Emmi G, Fortune F, G\u00fcl A, Kirino Y, Lee ES, Sfikakis PP, Shahram F, Wallace GR (2021) Adamantiades-Beh\u00e7et\u2019s disease (Beh\u00e7et\u2019s disease) and COVID-19. J Eur Acad Dermatol Venereol 35(9):e541\u2013e543. https:\/\/doi.org\/10.1111\/jdv.17325","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5056_CR19","unstructured":"https:\/\/covid19asi.saglik.gov.tr\/TR-77707\/asi-uygulanacak-grup-siralamasi.html. Accessed 27 March 2021"},{"key":"5056_CR20","unstructured":"https:\/\/covid19.saglik.gov.tr\/TR-66301\/covid-19-rehberi.html. Accessed 2020\u02d72021"},{"issue":"7","key":"5056_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102575","volume":"19","author":"G Emmi","year":"2020","unstructured":"Emmi G, Bettiol A, Mattioli I, Silvestri E, Di Scala G, Urban ML, Vaglio A, Prisco D (2020) SARS-CoV-2 infection among patients with systemic autoimmune diseases. Autoimmun Rev 19(7):102575. https:\/\/doi.org\/10.1016\/j.autrev.2020.102575","journal-title":"Autoimmun Rev"},{"key":"5056_CR22","volume-title":"Biostatistics: a foundation for analysis in the health sciences","author":"WW Daniel","year":"1999","unstructured":"Daniel WW (1999) Biostatistics: a foundation for analysis in the health sciences, 7th edn. Wiley, New York","edition":"7"},{"key":"5056_CR23","unstructured":"https:\/\/covid19.saglik.gov.tr\/TR-66935\/genel-koronavirus-tablosu.html. Accessed September 2021"},{"key":"5056_CR24","unstructured":"https:\/\/data.tuik.gov.tr\/Bulten\/Index?p=37210. Accessed September 2021"},{"issue":"9","key":"5056_CR25","doi-asserted-by":"publisher","first-page":"e557","DOI":"10.1016\/S2665-9913(20)30227-7","volume":"2","author":"J Zhong","year":"2020","unstructured":"Zhong J, Shen G, Yang H, Huang A, Chen X, Dong L, Wu B, Zhang A, Su L, Hou X, Song S, Li H, Zhou W, Zhou T, Huang Q, Chu A, Braunstein Z, Rao X, Ye C, Dong L (2020) COVID-19 in patients with rheumatic disease in Hubei province, China: a multicentre retrospective observational study. Lancet Rheumatol 2(9):e557\u2013e564. https:\/\/doi.org\/10.1016\/S2665-9913(20)30227-7","journal-title":"Lancet Rheumatol"},{"key":"5056_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218946","author":"S Akiyama","year":"2020","unstructured":"Akiyama S, Hamdeh S, Micic D, Sakuraba A (2020) Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218946","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5056_CR27","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/S2665-9913(21)00151-X","volume":"3","author":"YH Shin","year":"2021","unstructured":"Shin YH, Shin JI, Moon SY, Jin HY, Kim SY, Yang JM, Cho SH, Kim S, Lee M, Park Y, Kim MS, Won HH, Hong SH, Kronbichler A, Koyanagi A, Jacob L, Smith L, Lee KH, Suh DI, Lee SW, Yon DK (2021) Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study. Lancet Rheumatol 3(10):e698\u2013e706. https:\/\/doi.org\/10.1016\/S2665-9913(21)00151-X","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"5056_CR28","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s00296-020-04626-0","volume":"40","author":"E Seyahi","year":"2020","unstructured":"Seyahi E, Poyraz BC, Sut N, Akdogan S, Hamuryudan V (2020) The psychological state and changes in the routine of the patients with rheumatic diseases during the coronavirus disease (COVID-19) outbreak in Turkey: a web-based cross-sectional survey. Rheumatol Int 40(8):1229\u20131238. https:\/\/doi.org\/10.1007\/s00296-020-04626-0","journal-title":"Rheumatol Int"},{"key":"5056_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620938149","author":"W Miesbach","year":"2020","unstructured":"Miesbach W, Makris M (2020) COVID-19: coagulopathy, risk of thrombosis, and the rationale for anticoagulation. Clin Appl Thromb Hemost. https:\/\/doi.org\/10.1177\/1076029620938149 (PMID: 32677459; PMCID: PMC7370334)","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"5056_CR30","doi-asserted-by":"publisher","first-page":"e171","DOI":"10.1016\/S2665-9913(21)00003-5","volume":"3","author":"P Mehta","year":"2021","unstructured":"Mehta P, Haskard DO, Laffan MA, Chambers RC, Hunt BJ (2021) Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis. Lancet Rheumatol. 3(3):e171\u2013e172. https:\/\/doi.org\/10.1016\/S2665-9913(21)00003-5 (Epub 2021 Jan 7. PMID: 33521654; PMCID: PMC7832098)","journal-title":"Lancet Rheumatol."},{"issue":"9","key":"5056_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003379","volume":"17","author":"CT Rentsch","year":"2020","unstructured":"Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT Jr, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holodniy M, Lo RV 3rd, Akg\u00fcn KM, Crothers K, Taddei TH, Freiberg MS, Justice AC (2020) Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: a nationwide cohort study. PLoS Med. 17(9):e1003379. https:\/\/doi.org\/10.1371\/journal.pmed.1003379 (PMID: 32960880; PMCID: PMC7508372)","journal-title":"PLoS Med."},{"issue":"12","key":"5056_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243414","volume":"15","author":"JA Trubiano","year":"2020","unstructured":"Trubiano JA, Vogrin S, Smibert OC, Marhoon N, Alexander AA, Chua KYL, James FL, Jones NRL, Grigg SE, Xu CLH, Moini N, Stanley SR, Birrell MT, Rose MT, Gordon CL, Kwong JC, Holmes NE (2020) COVID-MATCH65-A prospectively derived clinical decision rule for severe acute respiratory syndrome coronavirus 2. PLoS ONE 15(12):e0243414. https:\/\/doi.org\/10.1371\/journal.pone.0243414","journal-title":"PLoS ONE"},{"issue":"6","key":"5056_CR33","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1111\/add.15276","volume":"116","author":"D Simons","year":"2021","unstructured":"Simons D, Shahab L, Brown J, Perski O (2021) The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). Addiction 116(6):1319\u20131368. https:\/\/doi.org\/10.1111\/add.15276","journal-title":"Addiction"},{"key":"5056_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntaa121","author":"P Tsigaris","year":"2020","unstructured":"Tsigaris P, Teixeira da Silva JA (2020) Smoking Prevalence and COVID-19 in Europe. Nicotine Tob Res. https:\/\/doi.org\/10.1093\/ntr\/ntaa121","journal-title":"Nicotine Tob Res"},{"issue":"20","key":"5056_CR35","doi-asserted-by":"publisher","first-page":"7394","DOI":"10.3390\/ijerph17207394","volume":"17","author":"J Gonz\u00e1lez-Rubio","year":"2020","unstructured":"Gonz\u00e1lez-Rubio J, Navarro-L\u00f3pez C, L\u00f3pez-N\u00e1jera E, L\u00f3pez-N\u00e1jera A, Jim\u00e9nez-D\u00edaz L, Navarro-L\u00f3pez JD, N\u00e1jera A (2020) A systematic review and meta-analysis of hospitalised current smokers and COVID-19. Int J Environ Res Public Health 17(20):7394. https:\/\/doi.org\/10.3390\/ijerph17207394","journal-title":"Int J Environ Res Public Health"},{"issue":"11","key":"5056_CR36","doi-asserted-by":"publisher","first-page":"204062232093576","DOI":"10.1177\/2040622320935765","volume":"25","author":"K Farsalinos","year":"2020","unstructured":"Farsalinos K, Barbouni A, Poulas K, Polosa R, Caponnetto P, Niaura R (2020) Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. Ther Adv Chronic Dis 25(11):2040622320935765. https:\/\/doi.org\/10.1177\/2040622320935765","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"5056_CR37","doi-asserted-by":"publisher","first-page":"2001340","DOI":"10.1183\/13993003.01340-2020","volume":"55","author":"JM Leung","year":"2020","unstructured":"Leung JM, Yang CX, Sin DD (2020) Reply to: \u201cCurrent smoking is not associated with COVID-19.\u201d Eur Respir J 55(6):2001340. https:\/\/doi.org\/10.1183\/13993003.01340-2020","journal-title":"Eur Respir J"},{"issue":"2","key":"5056_CR38","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/jmv.26389","volume":"93","author":"RK Reddy","year":"2021","unstructured":"Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A (2021) The effect of smoking on COVID-19 severity: a systematic review and meta-analysis. J Med Virol 93(2):1045\u20131056. https:\/\/doi.org\/10.1002\/jmv.26389","journal-title":"J Med Virol"},{"issue":"9","key":"5056_CR39","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/ntr\/ntaa082","volume":"22","author":"R Patanavanich","year":"2020","unstructured":"Patanavanich R, Glantz SA (2020) Smoking is associated With COVID-19 progression: a meta-analysis. Nicotine Tob Res 22(9):1653\u20131656. https:\/\/doi.org\/10.1093\/ntr\/ntaa082","journal-title":"Nicotine Tob Res"},{"issue":"8","key":"5056_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1136\/thx.49.8.825","volume":"49","author":"JA Dye","year":"1994","unstructured":"Dye JA, Adler KB (1994) Effects of cigarette smoke on epithelial cells of the respiratory tract. Thorax 49(8):825\u2013834. https:\/\/doi.org\/10.1136\/thx.49.8.825","journal-title":"Thorax"},{"issue":"6","key":"5056_CR41","doi-asserted-by":"publisher","first-page":"2001116","DOI":"10.1183\/13993003.01116-2020","volume":"55","author":"P Russo","year":"2020","unstructured":"Russo P, Bonassi S, Giacconi R, Malavolta M, Tomino C, Maggi F (2020) COVID-19 and smoking: is nicotine the hidden link? Eur Respir J 55(6):2001116. https:\/\/doi.org\/10.1183\/13993003.01116-2020","journal-title":"Eur Respir J"},{"issue":"10","key":"5056_CR42","doi-asserted-by":"publisher","first-page":"575","DOI":"10.12968\/hmed.2008.69.10.31317","volume":"69","author":"DS Yang","year":"2008","unstructured":"Yang DS, Taylor SR, Lightman SL (2008) Interferon-alpha in the management of patients with Beh\u00e7et\u2019s disease. Br J Hosp Med (Lond) 69(10):575\u2013579. https:\/\/doi.org\/10.12968\/hmed.2008.69.10.31317","journal-title":"Br J Hosp Med (Lond)"},{"issue":"3","key":"5056_CR43","first-page":"255","volume":"1","author":"L Lai","year":"2006","unstructured":"Lai L, Hui CK, Leung N, Lau GK (2006) Pegylated interferon alpha-2a (40 kDa) in the treatment of chronic hepatitis B. Int J Nanomedicine. 1(3):255\u201362 (PMID: 17717966; PMCID: PMC2426802)","journal-title":"Int J Nanomedicine."},{"issue":"4","key":"5056_CR44","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.bpg.2012.09.013","volume":"26","author":"JJ Feld","year":"2012","unstructured":"Feld JJ (2012) Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. Best Pract Res Clin Gastroenterol 26(4):429\u2013444. https:\/\/doi.org\/10.1016\/j.bpg.2012.09.013","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"11","key":"5056_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.615275.Erratumfor:FrontImmunol.2020May15;11:1061","volume":"27","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, Wang ZH, Tebbutt SJ, Kollmann TR, Fish EN (2020) Corrigendum: interferon-\u03b12b treatment for COVID-19. Front Immunol 27(11):615275. https:\/\/doi.org\/10.3389\/fimmu.2020.615275.Erratumfor:FrontImmunol.2020May15;11:1061","journal-title":"Front Immunol"},{"issue":"24","key":"5056_CR46","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1001\/jama.290.24.3222","volume":"290","author":"MR Loutfy","year":"2003","unstructured":"Loutfy MR, Blatt LM, Siminovitch KA, Ward S, Wolff B, Lho H, Pham DH, Deif H, LaMere EA, Chang M, Kain KC, Farcas GA, Ferguson P, Latchford M, Levy G, Dennis JW, Lai EK, Fish EN (2003) Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 290(24):3222\u20133228. https:\/\/doi.org\/10.1001\/jama.290.24.3222","journal-title":"JAMA"},{"key":"5056_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd4570","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Bastard P, Liu Z et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science. https:\/\/doi.org\/10.1126\/science.abd4570","journal-title":"Science."},{"issue":"6504","key":"5056_CR48","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1126\/science.abc6027","volume":"369","author":"J Hadjadj","year":"2020","unstructured":"Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, P\u00e9r\u00e9 H, Charbit B, Bondet V, Chenevier-Gobeaux C, Breillat P, Carlier N, Gauzit R, Morbieu C, P\u00e8ne F, Marin N, Roche N, Szwebel TA, Merkling SH, Treluyer JM, Veyer D, Mouthon L, Blanc C, Tharaux PL, Rozenberg F, Fischer A, Duffy D, Rieux-Laucat F, Kern\u00e9is S, Terrier B (2020) Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369(6504):718\u2013724. https:\/\/doi.org\/10.1126\/science.abc6027","journal-title":"Science"},{"issue":"6","key":"5056_CR49","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2174\/1381612824666180123110042","volume":"24","author":"C Angelidis","year":"2018","unstructured":"Angelidis C, Kotsialou Z, Kossyvakis C, Vrettou AR, Zacharoulis A, Kolokathis F, Kekeris V, Giannopoulos G (2018) Colchicine Pharmacokinetics and Mechanism of Action. Curr Pharm Des 24(6):659\u2013663. https:\/\/doi.org\/10.2174\/1381612824666180123110042","journal-title":"Curr Pharm Des"},{"issue":"6","key":"5056_CR50","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ejim.2010.09.010","volume":"21","author":"G Cocco","year":"2010","unstructured":"Cocco G, Chu DC, Pandolfi S (2010) Colchicine in clinical medicine. A guide for internists. Eur J Intern Med. 21(6):503\u20138. https:\/\/doi.org\/10.1016\/j.ejim.2010.09.010","journal-title":"Eur J Intern Med."},{"issue":"4","key":"5056_CR51","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/cmdc.201800641","volume":"14","author":"M Richter","year":"2019","unstructured":"Richter M, Boldescu V, Graf D, Streicher F, Dimoglo A, Bartenschlager R, Klein CD (2019) Synthesis, biological evaluation, and molecular docking of combretastatin and colchicine derivatives and their hCE1-Activated Prodrugs as Antiviral Agents. ChemMedChem 14(4):469\u2013483. https:\/\/doi.org\/10.1002\/cmdc.201800641","journal-title":"ChemMedChem"},{"issue":"6","key":"5056_CR52","doi-asserted-by":"publisher","first-page":"2013136","DOI":"10.1001\/jamanetworkopen.2020.13136","volume":"3","author":"SG Deftereos","year":"2020","unstructured":"Deftereos SG, Giannopoulos G, Vrachatis DA, Siasos GD, Giotaki SG, Gargalianos P, Metallidis S, Sianos G, Baltagiannis S, Panagopoulos P, Dolianitis K, Randou E, Syrigos K, Kotanidou A, Koulouris NG, Milionis H, Sipsas N, Gogos C, Tsoukalas G, Olympios CD, Tsagalou E, Migdalis I, Gerakari S, Angelidis C, Alexopoulos D, Davlouros P, Hahalis G, Kanonidis I, Katritsis D, Kolettis T, Manolis AS, Michalis L, Naka KK, Pyrgakis VN, Toutouzas KP, Triposkiadis F, Tsioufis K, Vavouranakis E, Martin\u00e8z-Dolz L, Reimers B, Stefanini GG, Cleman M, Goudevenos J, Tsiodras S, Tousoulis D, Iliodromitis E, Mehran R, Dangas G, Stefanadis C, GRECCO-19 investigators (2020) Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. JAMA Netw Open. 3(6):2013136. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.13136","journal-title":"JAMA Netw Open."},{"issue":"3","key":"5056_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0248276","volume":"16","author":"L Manenti","year":"2021","unstructured":"Manenti L, Maggiore U, Fiaccadori E, Meschi T, Antoni AD, Nouvenne A, Ticinesi A, Cerundolo N, Prati B, Delsante M, Gandoflini I, Donghi L, Gentile M, Farina MT, Oliva V, Zambrano C, Regolisti G, Palmisano A, Caminiti C, Cocchi E, Ferrari C, Riella LV, Cravedi P, Peruzzi L (2021) Reduced mortality in COVID-19 patients treated with colchicine: results from a retrospective, observational study. PLoS ONE 16(3):e0248276. https:\/\/doi.org\/10.1371\/journal.pone.0248276","journal-title":"PLoS ONE"},{"issue":"1","key":"5056_CR54","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001455","volume":"7","author":"MI Lopes","year":"2021","unstructured":"Lopes MI, Bonjorno LP, Giannini MC, Amaral NB, Menezes PI, Dib SM, Gigante SL, Benatti MN, Rezek UC, Emrich-Filho LL, Sousa BAA, Almeida SCL, Luppino Assad R, Veras FP, Schneider A, Rodrigues TS, Leiria LOS, Cunha LD, Alves-Filho JC, Cunha TM, Arruda E, Miranda CH, Pazin-Filho A, Auxiliadora-Martins M, Borges MC, Fonseca BAL, Bollela VR, Del-Ben CM, Cunha FQ, Zamboni DS, Santana RC, Vilar FC, Louzada-Junior P, Oliveira RDR (2021) Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open 7(1):e001455. https:\/\/doi.org\/10.1136\/rmdopen-2020-001455","journal-title":"RMD Open"},{"issue":"8","key":"5056_CR55","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","volume":"9","author":"JC Tardif","year":"2021","unstructured":"Tardif JC, Bouabdallaoui N, L\u2019Allier PL, Gaudet D, Shah B, Pillinger MH, Lopez-Sendon J, da Luz P, Verret L, Audet S, Dupuis J, Denault A, Pelletier M, Tessier PA, Samson S, Fortin D, Tardif JD, Busseuil D, Goulet E, Lacoste C, Dubois A, Joshi AY, Waters DD, Hsue P, Lepor NE, Lesage F, Sainturet N, Roy-Clavel E, Bassevitch Z, Orfanos A, Stamatescu G, Gr\u00e9goire JC, Busque L, Lavall\u00e9e C, H\u00e9tu PO, Paquette JS, Deftereos SG, Levesque S, Cossette M, Nozza A, Chabot-Blanchet M, Dub\u00e9 MP, Guertin MC, Boivin G, COLCORONA Investigators (2021) Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir Med. 9(8):924\u2013932. https:\/\/doi.org\/10.1016\/S2213-2600(21)00222-8","journal-title":"Lancet Respir Med."},{"issue":"7","key":"5056_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102566","volume":"19","author":"O Gendelman","year":"2020","unstructured":"Gendelman O, Amital H, Bragazzi NL, Watad A, Chodick G (2020) Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev 19(7):102566. https:\/\/doi.org\/10.1016\/j.autrev.2020.102566","journal-title":"Autoimmun Rev"},{"key":"5056_CR57","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211002684","author":"A Madrid-Garc\u00eda","year":"2021","unstructured":"Madrid-Garc\u00eda A, P\u00e9rez I, Colomer JI, Le\u00f3n-Mateos L, Jover JA, Fern\u00e1ndez-Guti\u00e9rrez B, Ab\u00e1solo-Alcazar L, Rodr\u00edguez-Rodr\u00edguez L (2021) Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis. Ther Adv Musculoskelet Dis. https:\/\/doi.org\/10.1177\/1759720X211002684","journal-title":"Ther Adv Musculoskelet Dis."},{"issue":"4","key":"5056_CR58","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00296-021-04809-3","volume":"41","author":"K Nas","year":"2021","unstructured":"Nas K, Eryilmaz N, Geyik MF, Alta\u015f A (2021) COVID-19 in patients with familial Mediterranean fever treated with colchicine: case based review. Rheumatol Int 41(4):811\u2013817. https:\/\/doi.org\/10.1007\/s00296-021-04809-3","journal-title":"Rheumatol Int"},{"key":"5056_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218707","author":"R Bourguiba","year":"2020","unstructured":"Bourguiba R, Delplanque M, Vinit C, Ackermann F, Savey L, Grateau G, Hentgen V, Georgin-Lavialle S (2020) Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218707","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"5056_CR60","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41584-020-00562-2.PMID:33339986;PMCID:PMC7747184","volume":"17","author":"KL Hyrich","year":"2021","unstructured":"Hyrich KL, Machado PM (2021) Rheumatic disease and COVID-19: epidemiology and outcomes. Nat Rev Rheumatol 17(2):71\u201372. https:\/\/doi.org\/10.1038\/s41584-020-00562-2.PMID:33339986;PMCID:PMC7747184","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"5056_CR61","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00038-020-01390-7","volume":"65","author":"V Jain","year":"2020","unstructured":"Jain V, Yuan JM (2020) Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health 65(5):533\u2013546. https:\/\/doi.org\/10.1007\/s00038-020-01390-7","journal-title":"Int J Public Health"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-05056-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-05056-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-05056-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T08:33:32Z","timestamp":1673858012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-05056-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,25]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5056"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-05056-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,25]]},"assertion":[{"value":"21 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Guzin Ozcifci, Tahacan Aydin, Zeynep Atli, Ilker Inanc Balkan, Mert Oztas, Yesim Ozguler, Melike Melikoglu, Izzet Fresko and Vedat Hamuryudan declare that they have no conflict of interest. Fehmi Tabak, has received honoraria, consulting or speaker fees from GSK, MSD, AbbVie and Gilead. Serdal Ugurlu has received honoraria, consulting or speaker fees from Novartis, Pfizer, Lilly and Celltrion. Gulen Hatemi has received research grant from Celgene, honoraria consulting or speaker fees from AbbVie, Amgen, Celgene, Lilly, Novartis and UCB Pharma. Emire Seyahi has received honoraria, consulting or speaker fees from Novartis, Pfizer, AbbVie and Gilead.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}